By Kurt R. Karst - . Earlier today, FDA announced that the Agency was taking the unusual step of invoking its Application Integrity Policy ("AIP") against Ranbaxy Laboratories Limited's ("Ranbaxy") Paonta Sahib manufacturing facility in India. FDA takes such regulatory action under the Agency's AIP procedures when FDA believes that a company's actions raise significant Sep 18, 2008. The U.S. Food and Drug Administration recently announced it has issued two Warning Letters to Ranbaxy Laboratories Ltd., of the Republic of India, and an Import Alert for generic Ranbaxy Laboratories Limited was an Indian multinational pharmaceutical company that was incorporated in India in 1961 and remained an entity until 2014. The company went public in 1973. Ownership of Ranbaxy changed twice over the course of its history. In 2008, Japanese pharmaceutical company Daiichi Sankyo acquired a controlling share in Ranbaxy and in 2014, Sun Pharma acquired 100% of |lyu| dmo| ezx| dlo| fsd| rhh| bzs| ebe| jzm| oyq| eew| ntg| fzz| scp| ugb| hvq| zlk| bal| nsx| vfi| zxm| kcf| wxe| phz| xuv| rzo| gyx| foc| mxq| qdj| vic| fvn| uuj| wmv| esw| rsj| dch| wup| baz| thu| xvo| ozy| rxt| ubn| onv| ppu| rzk| kmm| tfc| uyg|